Otsuka reports solid US growth for Abilify
This article was originally published in Scrip
Executive Summary
US net sales of the atypical antipsychotic Abilify (aripiprazole) were $3.51 billion in calendar 2010, a 6% increase in local currency terms, new unaudited figures released by originator Otsuka Holdings show.